Form 4: Protagonist Therapeutics Director William D. Waddill Reports Stock Transactions

Director William D. Waddill of Protagonist Therapeutics reports the acquisition and disposal of common stock and stock options on September 10, 2024.

Summary

• On September 10, 2024, William D. Waddill, a director of Protagonist Therapeutics, engaged in transactions involving the company's stock.
• Waddill exercised stock options to acquire 8,000 shares of common stock at a price of $12.88 per share.
• Simultaneously, Waddill sold 8,000 shares of common stock at $45 per share.
• Following these transactions, Waddill directly owns 12,000 shares of Protagonist Therapeutics common stock.
• The sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2023.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the director's outlook on the company.

Positives

• The exercise of stock options demonstrates the director's belief in the company's future prospects.
• The sale of shares at $45 provides a profit for the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of company stock) buy or sell their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The transactions may provide liquidity to the director.
• The transactions provide transparency to shareholders regarding insider activity.

Key Dates